The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone refractory prostate cancer

Urologic Clinics of North America

Volumn 24, Issue 2, 1997, Pages 433-437

  Smith, D C ^a   Pienta, K J ^a  

^a MSRB I   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTRAMUSTINE; ETOPOSIDE; GEMCITABINE; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN; RHENIUM 186; SURAMIN; TRIMETREXATE; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME;

EID: 0030994033     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70390-6     Document Type: Article

References (12)

1. J.B. Anderson K.C. Cain R.D. Gelber Analysis of survival by tumor response J Clin Oncol 1 1983 710 719
2. J.E. Fowler P. Pandey L.E. Seaver Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer J Urol 153 1994 1860 1865
3. G.R. Hudes R. Greenberg R.L. Krigel Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone refractory prostate cancer J Clin Oncol 10 1992 1754 1761
4. W.K. Kelly H.I. Scher M. Mazumdar Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer J Clin Oncol 11 1993 607 615
5. K. Kobayashi E.E. Vokes M.J. Ratain Survival of prostate cancer patients treated with suramin by intermittent infusion without adaptive control: Possible negative impact of prior flutamide therapy on survival Proceedings of the American Society of Clinical Oncology 15 1996 481
6. H. Matzkin P. Eber B. Todd Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer Cancer 70 1992 2302 2309
7. C. Myers M. Cooper C. Stein Suramin: A novel growth factor antagonist with activity in hormone refractory prostate cancer J Clin Oncol 10 1992 881 889
8. K.J. Pienta B. Redman M. Hussain Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate J Clin Oncol 12 1994 2005 2012
9. H.I. Scher T. Curley N. Geller Trimetrexate in prostatic cancer: Preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease J Clin Oncol 8 1990 1830 1838
10. A.D. Seidman H.I. Scher D. Petrylak Estramustine and vinblastine use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer J Urol 147 1992 931 934
11. R. Sridhara M.A. Eisenberger V.J. Sinibaldi Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy J Clin Oncol 13 1995 2944 2953
12. C.A. Stein R.V. LaRocca R. Thomas Suramin: An anticancer drug with a unique mechanism of action J Clin Oncol 7 1989 499 508